^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FGFR2-CCDC6 fusion

    i
    Other names: FGFR2, BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25, Fibroblast growth factor receptor 2, CCDC6, Coiled-Coil Domain Containing 6, Papillary Thyroid Carcinoma-Encoded Protein, Coiled-Coil Domain-Containing Protein 6, D10S170, TST1, DNA Segment Single Copy Probe PH4 (Transforming Sequence Thyroid-1, DNA Segment On Chromosome 10 (Unique) 170, Protein H4, PTC, TPC, H4
    Entrez ID:
    2263; 8030
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    4years
    Ponatinib inhibits growth of patient-derived xenograft of cholangiocarcinoma expressing FGFR2-CCDC6 fusion protein in nude mice (PubMed, Nan Fang Yi Ke Da Xue Xue Bao)
    Ponatinib can regulate FGFR signaling to inhibit the proliferation and induce apoptosis of tumor cells in mice bearing patient-derived cholangiocarcinoma xenograft with FGFR2 fusion. FGFR inhibitor can serve as a treatment option for patients with cholangiocarcinoma with FGFR2 fusion.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2) • CCDC6 (Coiled-Coil Domain Containing 6) • CASP3 (Caspase 3) • FRS2 (Fibroblast Growth Factor Receptor Substrate 2) • CD31 (Platelet and endothelial cell adhesion molecule 1)
    |
    FGFR2 fusion • FGFR fusion • FGFR2-CCDC6 fusion • CD31 expression
    |
    cisplatin • gemcitabine • Iclusig (ponatinib)